Palisade Bio Inc is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in the field of gastrointestinal health
The company specializes in the advancement of its proprietary drug candidates aimed at improving patient outcomes, particularly in surgery-related settings and conditions affecting the digestive system. By leveraging its expertise in drug formulation and delivery, Palisade Bio seeks to enhance the safety and effectiveness of treatments, ultimately striving to enhance the quality of life for patients dealing with complex gastrointestinal disorders.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Palisade Bio entered into a collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative colitis (UC) therapy and provides the company access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.02% to 37,741.96 while the NASDAQ fell 0.20% to 15,853.39. The S&P 500 also fell, dropping, 0.28% to 5,047.76.
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
